SELDI蛋白芯片检测技术在小儿脑膜炎分型中的应用

目的 利用表面增强激光解析离子化飞行时间质谱(SELDI-TOF-MS)及蛋白芯片技术检测不同类型小儿脑膜炎患儿脑脊液蛋白质峰谱的表达情况,为临床建立一种方便、快速、敏感、高效的诊断新技术.方法 采集87例脑膜炎患儿(化脓性脑膜炎21例,病毒性脑炎29例,结核性脑膜炎37例)脑脊液样本,利用弱阳离子芯片CM10和SELDI-TOF-MS技术分析脑脊液中的差异表达蛋白质峰,联合应用明显差异表达的蛋白质峰建立分类决策树,随机选取50例样本对决策树进行盲法检验,得出决策树模型的分类准确率.结果 共获得127个有效蛋白质峰,利用m/z=6206,m/z=8577和m/z=11535三个显著差异表达的蛋白质峰成功建立分类决策树,准确度为96%(48/50),敏感度为100%(21/21),特异度为93.1%(27/29).结论 SELDI-TOF-MS及蛋白芯片技术可快速、准确地鉴别三种常见的小儿脑膜炎类型,为今后临床诊断提供了新的借鉴和参考.     

特发性肺纤维化患者支气管肺泡灌洗液中特异性蛋白标记物研究

目的 分析特发性肺纤维化(IPF)患者支气管肺泡灌洗液(BALF)中蛋白质谱变化,寻找特异性蛋白标记物,评价这些标记物对IPF的诊断价值及临床应用前景.方法 收集IPF患者及对照组BALF标本,应用表面增强激光解析/电离飞行时间质谱(SELDI-TOF-MS)技术筛选差异蛋白.通过非线性支持向量机方法建立诊断模型,并留一交叉验证法评估各模型的预测效果.结果 IPF患者BALF中筛选出8个表达有显著差异的蛋白质峰,其中检测效率最高的4个低表达蛋白质峰质荷比(m/z)分别为1947.634、1975.519、2488.535及4950.230.以这4个蛋白质峰组合建立诊断模型,其特异性和敏感性均为100%.结论 应用SELDI-TOF-MS技术分析获得的低分子量蛋白质峰在诊断中具有较高的灵敏度和特异性,这些小分子可能在IPF发病中起重要作用.     

乳腺癌患者血清蛋白质指纹图谱检测及其临床意义

目的用表面增强激光解吸离子化飞行时间质谱(SELDI-TOF-MS)和蛋白质芯片检测乳腺癌患者血清蛋白质指纹图谱，初步探讨筛选候选肿瘤标志物建立的诊断模型在乳腺癌诊断中的临床意义。方法用SELDI-TOF-MS技术及配套蛋白质芯片检测49例乳腺癌和37例非乳腺癌疾病患者的血清蛋白质指纹图谱，并运用SPSS10．0软件判别分析处理数据和筛选标志物，以建立诊断模型。结果6个蛋白质峰[8611、16827、25711、28931、25485和2437质荷比(m/z)]组合构建的诊断模型Ⅰ鉴别乳腺癌和非乳腺癌疾病的敏感性为81．6％(40/49)，特异性为78．4％(29/37)。6个蛋白质峰(4470、10854、19193、3883、2011和7470m/z)组合的诊断模型Ⅱ鉴别Ⅰ期乳腺癌与非乳腺癌疾病的敏感性为80．0％(12/15)，特异性为89．2％(33/37)。5个蛋白质峰(2726、27014、2247、4477和19333m/z)组合的诊断模型Ⅲ鉴别Ⅰ期与Ⅱ～Ⅳ期乳腺癌的敏感性为91．2％(31/34)，特异性为93．3％(14/15)。结论SELDI-TOF-MS在乳腺癌的诊断尤其是早期诊断、术前分期及候选肿瘤标志物筛选等方面具有一定价值，值得进一步深入研究。     

血清蛋白质谱与人工神经网络模型诊断卵巢癌的应用性研究

目的 建立筛选卵巢癌血清蛋白质谱与人工神经网络诊断模型的研究。方法 用H4(疏水表面)蛋白芯片结合表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)技术检测卵巢癌患者和健康人血清样本的蛋白质谱，同时采用人工神经网络筛选差异蛋白以建立诊断模型。结果 用SELDI-TOF-MS技术和H4蛋白芯片从47例卵巢癌和29名健康人血清中，筛选出4个有明显表达差异的蛋白，其质荷比(m／z)分别为5881、7553、6652和9391。用其中的18名健康人和29例卵巢癌患者样本作训练集和交叉验证后，再用筛选出的4个差异蛋白质建立人工神经网络预测模型。然后，对11名健康人和18例卵巢癌患者样本进行盲法测试，以验证该模型。结果显示，我们建立的诊断模型对卵巢癌检测的敏感性为100％，特异性为90．9％，阳性率为94．7％。结论 血清蛋白质谱与人工神经网络模型对小样本的卵巢癌诊断具有较高的敏感性和特异性，可扩大样本进行深入的应用性研究。     

应用表面增强激光解吸电离飞行时间质谱联合磁珠技术寻找肺癌血清蛋白标志物

目的建立肺癌蛋白质指纹图谱诊断模型,探讨用于肺癌早期诊断及手术疗效评估的血清蛋白标志物。方法收集38例肺癌患者、12例肺部良性肿瘤患者及32名正常对照者的血清标本,应用表面增强激光解吸电离飞行时间质谱(surface-enhanced laser desorption/ionization time-of-flight mass spectrometry,SELDI-TOF-MS)联合磁珠技术,获得蛋白质指纹图谱,采用BPS分析软件对数据分组及相关性进行分析,初步建立肺癌的血清蛋白质指纹图谱诊断模型,并验证其诊断效率;同时对比肺癌患者手术前后的差异蛋白质谱,结合肺癌的诊断模型,选取合适的蛋白作为肺癌手术疗效的观察指标。结果在质荷比为1000~50 000范围内,肺癌患者、肺部良性肿瘤患者和正常对照者之间共检测到215个蛋白质峰。其中,质荷比为1115.37、1929.70、3217.57、3246.34、3318.57、11 508.90的6个蛋白质峰表达差异具有统计学意义(P0.05)。决策树模型对肺癌的原始判别敏感性为92.11%(35/38),特异性为90.91%(40/44);交叉验证敏感性为86.67%(13/15),特异性为86.67%(13/15)。其中质荷比为1115.37、1929.70、3246.34和11 508.90的蛋白质峰在肺癌患者中明显升高(P0.05),当肺癌患者手术治疗后表达量较术前明显降低(P0.01),表明这4个蛋白质峰对肺癌的诊断及疗效判定具有潜在应用价值。结论应用SELDI-TOF-MS技术建立的肺癌血清蛋白质指纹图谱诊断模型具有较高的敏感性和特异性,为发现肺癌早期生物标志物并判断疗效奠定基础。     

SELDI—TOF—MS技术对鼻咽癌裸鼠移植模型早期蛋白组学研究

目的 快速筛选人鼻咽癌裸鼠移植瘤模型血清中差异表达蛋白,为鼻咽癌的早期诊断提供特有的血清微量蛋白标志物.方法 采用SELDI-TOF-MS蛋白芯片技术检测10只正常裸鼠和50只人鼻咽癌裸鼠移植瘤模型在不同时间血清中的蛋白指纹图谱,用CiphergenProteinChip3.0软件自动采集数据,CiphergenBiomakerWizard3.1版软件统计分析筛选对照组与实验组间的差异表达蛋白.结果 对照组与实验组间检出15个差异表达的蛋白质(P<0.0001),分子量主要集中在2～20kD以内,大多数标志蛋白在实验组中表达明显增高,少数为低表达.尤其是质荷比(M/Z)为6741,8019,8102,8615的四个蛋白质在接种癌细胞后表达逐渐增强,质荷比(M/Z)为14740,15484的两个蛋白质表达逐渐减弱.结论 鼻咽癌细胞在裸鼠体内生长过程中,其裸鼠血清中出现明显的差异表达蛋白质,经临床盲法验证有可能成为鼻咽癌早期诊断的微量蛋白标志物.     

应用金芯片技术预测肾功能损害的临床应用研究

目的探讨利用金(Au)芯片检测尿蛋白质指纹图谱在预测肾功能损害中的应用价值。方法利用表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)技术及Au芯片检测186例肾病患者和188例对照者尿蛋白质指纹图,分析肾病患者与对照组尿蛋白质表达差异并筛选标志蛋白质,结合人工神经网络(ANN)技术建立智能预测模型,评价其诊断肾病的应用价值。对部分差异蛋白质通过电喷雾四级杆飞行时间质谱(ESI-Q-TOF)进行鉴定。用免疫散射比浊法检测尿微球蛋白并与蛋白质指纹图谱结果比较,评价SELDI-TOF-MS检测性能。结果肾病患者与对照者尿中共检测到214个蛋白质峰,有69个蛋白质峰差异有统计学意义(P<0.05),筛选其中质荷比(m/z)11 735、23 770、51 720、58 720、67 650、80 045、91 240蛋白质建立的ANN模型预测肾功能损害的灵敏度为98.8%(85/86),特异度为96.6%(85/88)。蛋白鉴定结果表明m/z 11 735、23 770、67 650、80 045蛋白质分别为β2-微球蛋白、α1-微球蛋白、白蛋白、转铁蛋白。SELDI-TOF-MS检测微球蛋白较免疫散射比...     

尿蛋白标志物模型早期诊断糖尿病肾病的临床应用

目的 寻找基于蛋白质组学技术早期、快速诊断糖尿病肾病的尿蛋白标志物模型,并探讨其临床应用价值.方法 应用表面增强激光解析电离飞行时间质谱(surface-enhanced laser dosorption-ionization time of flight mass spectrometry,SELDI-TOF-MS)技术及Au芯片(proteinehip gold array)检测292例患者尿蛋白质谱,包括129例糖尿病肾病和163例对照者(61例糖尿病及102名健康体检者).获得的蛋白质谱数据用Biomaker Wizard 3.1软件筛选差异蛋白,通过生物标志模型软件(biomarker patterns software,BPS)建立决策树辨别分析模型,评价其临床诊断价值.对部分筛选的差异蛋白通过比对标准蛋白质谱数据,根据分子量大小进行初步鉴定.结果糖尿病肾病患者与对照者尿液中差异表达的蛋白质峰有40个,其丰度值两组间比较差异均有统计学意义(t值为-9.81～24.52,P均<0.05),通过BPS自动筛选66 916质荷比(m/z)蛋白建立的模型诊断糖尿病肾病敏感度为98.7%(78/79),特异度98.2%(111/113).对糖尿病和糖尿病肾病患者尿蛋白质谱图分析后得到24个差异蛋白质峰,其丰度值两组间比较差异均有统计学意义(t值为-6.95～14.45,P均<0.05),BPS筛选4 008、11 619、66 916 m/z蛋白建立模型区分糖尿病与糖尿病肾病的敏感度(129/129)和特异度(61/61)均为100%.通过比对标准蛋白质谱数据,糖尿病肾病患者尿差异蛋白中m/z11 619、23 529、66 916和79 378,可能为β_2-微球蛋白、α1-微球蛋白、白蛋白和转铁蛋白.结论 基于SELDI-TOF-MS及Au芯片技术检测尿蛋白质谱在鉴别蛋白尿来源、糖尿病肾病的早期快速诊断及肾脏损害评估具有重要应用价值.     

血小板裂解液差异蛋白在原发免疫性血小板减少症诊断中的临床应用研究

目的通过对原发免疫性血小板减少症(ITP)患者血小板裂解液差异蛋白的研究,了解其与ITP发病的关系,为ITP的诊断建立一种简便快速、灵敏度高、特异性好的实验方法。方法应用表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)技术检测64例ITP患者及42例健康者血小板裂解液,获得血小板蛋白质谱图,筛选出差异蛋白,结合人工神经网络(ANN),建立ITP诊断模型。结果质荷比(m/z)为3 549.17、7 678.09的蛋白在ITP组中高表达,质荷比为5 328.29、7 894.32的蛋白低表达。诊断模型的灵敏度93.3%,特异度82.6%。结论基于血小板蛋白质谱建立的ANN模型可能对ITP的诊断具有一定的临床价值。     

SELDI蛋白质芯片技术在肝癌中的应用

目的应用SELDI蛋白质芯片技术筛选甲胎蛋白(AFP)低浓度阳性的肝癌患者和肝病患者的血清差异蛋白表达谱,并构建相应的诊断模型。方法应用表面增强激光解吸电离飞行时间质谱技术和CM10芯片分别检测AFP低浓度阳性肝癌患者28例与34例肝病患者的血清蛋白表达谱,获得差异蛋白峰并建立疾病诊断模型。结果在质荷比2 000～50 000范围内共检测到39个蛋白峰,29个蛋白峰差异有统计学意义(P<0.05),其中在AFP低浓度阳性肝癌组血清中有5个蛋白峰上调,24个蛋白峰下调。以质荷比为6 452构建的诊断模型中区分AFP低浓度阳性肝癌患者与肝病患者的准确率为85.5%(53/62),灵敏度为82.1%(23/28),特异度为88.2%(30/34),阳性预测值为85.2%(23/27),阴性预测值为85.7%(30/35),阳性似然比为6.982,阴性似然比为0.202。结论应用SELDI蛋白芯片技术建立的疾病诊断模型能在整体上提高血清AFP低浓度阳性结果的肝癌诊断效率。     

Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?

Meningiomas are cytogenetically heterogeneous tumors in which chromosome gains and losses frequently occur. Based on the intertumoral cytogenetic heterogeneity of meningiomas, hypothetical models of clonal evolution have been proposed in these tumors which have never been confirmed at the intratumoral cell level. The aim of this study was to establish the intratumoral patterns of clonal evolution associated with chromosomal instability in individual patients as a way to establish tumor progression pathways in meningiomas and their relationship with tumor histopathology and behavior. A total of 125 meningioma patients were analyzed at diagnosis. In all cases, multicolor interphase fluorescence in situ hybridization (iFISH) studies were performed on fresh tumor samples for the detection of quantitative abnormalities for 11 different chromosomes. In addition, overall tumor cell DNA content was measured in parallel by flow cytometry. iFISH studies were also performed in parallel on tissue sections in a subset of 30 patients. FISH studies showed that 56 (45%) of the 125 cases analyzed had a single tumor cell clone, all these cases corresponding to histologically benign grade I tumors. In the remaining cases (55%) more than one tumor cell clone was identified: two in 45 cases (36%), three in 19 (15%), and four or more clones in five cases (4%). Overall, flow cytometric analysis of cell DNA contents showed the presence of DNA aneuploidy in 44 of these cases (35%), 30% corresponding to DNA hyperdiploid and 5% to hypodiploid cases; from the DNA aneuploid cases, 35 (28%) showed two clones and 9 (7%) had three or more clones. A high degree of correlation (r >/= 0.89; P < 0.001) was found between FISH and flow cytometry as regards the overall quantitative DNA changes detected with both techniques, the former being more sensitive. Among the cases with chromosome abnormalities, the earliest tumor cell clone observed was frequently characterized by the loss of one or more chromosomes (64% of all meningiomas); loss of either a single chromosome 22 or, less frequently, of a sex chromosome (X or Y) and del (1p) was commonly found as the single initial cytogenetic aberration (30%, 5%, and 5% of the cases, respectively). Interestingly, an isolated loss of chromosome 22 was only found as the initial abnormality in one out of 14 atypical/anaplastic meningiomas, while the same cytogenetic pattern was present in the ancestral tumor cell clone of 32% of the benign tumors. Cytogenetic patterns based on chromosome gains were found in the ancestral tumor cell clone in 4% of the patients, 2% corresponding to tetraploid tumors. Overall, cytogenetic evolution of the earliest tumor cell clones was frequently associated with tetraploidization (31%). Our results show that meningiomas are genetically heterogeneous tumors that display different patterns of numerical chromosome changes, with the presence of more than one tumor cell clone detected in almost half of the cases including all atypical/anaplastic cases. Interestingly, the pathways of intratumoral clonal evolution observed in the benign tumors were different from those observed in atypical/anaplastic meningiomas, suggesting that the latter tumors might not always represent a more advanced stage of histologically benign meningiomas.     

Delineation of brain tumor margins using intraoperative sononavigation: implications for tumor resection

PURPOSE: Sonography has been employed for real-time intraoperative delineation of tumor boundaries during resection of brain tumors. However, the variably hyperechoic appearance of brain edema or gliosis surrounding the brain may interfere with accurate depiction of tumor margins. The goal of the present study was to use sononavigation, which provides coregistration between real-time sonograms and MRI scans, to assess the accuracy of sonographic determination of tumor margins. METHODS: Sononavigation was performed on 12 brain tumors (7 metastatic brain tumors, 2 meningiomas, 1 anaplastic oligodendroglioma, 1 anaplastic pilocytic astrocytoma, and 1 anaplastic astrocytoma). Sonograms of tumor margins were categorized into 1 of 3 types: in type 1, the tumor margin was clearly visualized and corresponded to the margin of the enhanced lesion on MR scan in all areas; in type 2, the tumor margin was clearly seen in some areas but was obscure in others due to hyperechoic edema; and in type 3, the tumor margin was indistinguishable from surrounding tissues in all areas. RESULTS: Three metastatic brain tumors and 1 meningioma were categorized as type 1. Three metastatic brain tumors, 1 meningioma, and 1 anaplastic oligodendroglioma were categorized as type 2. The anaplastic pilocytic astrocytoma, 1 metastatic brain tumor (which consisted mainly of necrotic tissue), and the anaplastic astrocytoma were categorized as type 3. These data assist in determining whether the sonographic appearance of tumor margins is accurate and whether to rely on information from either sonography (type 1) or the sononavigation system when resecting tumor types 1, 2, and 3. CONCLUSIONS: Sononavigation can help categorize the sonographic tumor margins into 3 different patterns, and this categorization can assist in determining which imaging modalities are needed to better delineate the tumor margins for subsequent resection.     

脑膜瘤雌、孕激素受体表达与临床病理和预后的关系

目的：探讨脑膜瘤雌、孕激素受体表达与临床病理和预后的关系。方法：采用SABC免疫组化方法检测56例脑膜瘤组织中雌、孕激素受体表达，分析其与临床病理和预后的关系。结果：所有56例脑膜瘤组织中雌激素表达均为阴性，孕激素表达阳性率为60．7％（34／56），其中良性脑膜瘤组织中孕激素表达阳性率（69．6％）显著高于非良性脑膜瘤组织（20．0％），P〈0．01。统计分析显示，脑膜瘤孕激素表达与患者性别、组织亚型、肿瘤部位、切除程度无明显相关，而与肿瘤复发有关，复发脑膜瘤孕激素表达阳性率17．6％显著低于无复发脑膜瘤79．5％，P〈0.01。结论：脑膜瘤与雌激素无关，孕激素表达与脑膜瘤病理性质度复发有关，可作为脑膜瘤预后判定度治疗的重要参考指标。     

Rehabilitation outcomes in patients with brain tumors and acute stroke: comparative study of inpatient rehabilitation

OBJECTIVES: To investigate functional outcomes after hospital rehabilitation of patients surviving craniotomy for primary brain tumor excision compared with post-stroke patients. DESIGN: The database of the Neurological Rehabilitation Department "C" of Loewenstein Rehabilitation Center was used to investigate primary brain tumors and first ischemic and hemorrhagic stroke patients admitted for hospital rehabilitation during an 11-yr period, between January 1993 and August 2004. Particular attention was paid to age and sex distribution, onset-to-admission interval, length of stay, functional status at admission and discharge, functional gain (DeltaFI change) as measured by the FIM instrument. RESULTS: A total of 168 patients with craniotomy for primary brain tumor excision (128 intracranial meningiomas and 40 cerebral gliomas) and 1660 first-stroke patients were admitted to the department for rehabilitation during the study period. Mean patient age was 59.9 yrs in meningioma group, 54.1 yrs in the glioma group, and 60.4 yrs in the stroke group. In the meningioma and stroke groups, male patients were in the majority (62 and 70%); in the glioma group, there was equal sex distribution. On average, patients were admitted to rehabilitation treatment 13 days after meningioma excision, 34 days after glioma operation, and 21.6 days after stroke. Functional variables during inpatient rehabilitation were found to be similar in the all groups. Average FIM rating at admission was 80.07 in the meningioma group, 68.2 in the glioma group, and 70.4 in the stroke group. Average discharge FIM rating was 90.3 for patients with meningiomas, 80.7 for patients with gliomas, and 87.8 for stroke patients. Functional gain was 17.9 for meningioma patients, 17.2 for glioma patients, and 21.8 for stroke patients. Average length of stay was 24 days for the meningioma group, 23 days for the glioma group, and 75.4 days for stroke patients; 88.1% of stroke patients, 91.7% of meningioma patients, and 82.7% of glioma patients were discharged to their homes, and 5.4, 3.4, and 8.6%, respectively, were discharged to nursing homes. CONCLUSIONS: Patients with brain tumors can achieve good functional outcomes with a shorter length of stay.     

扩散张量成像及扩散张量纤维束成像在星形细胞瘤与脑膜瘤诊断中的价值

目的 探讨DTI及扩散张量纤维束成像(DTT)诊断星形细胞瘤与脑膜瘤的价值。方法 对22例经病理证实的脑肿瘤患者(不同级别星形细胞瘤12例,良性脑膜瘤10例),测量肿瘤实质区与健侧正常脑组织的平均ADC值和FA值,比较测值,并观察两种脑肿瘤对白质纤维束的影响。结果 星形细胞瘤及脑膜瘤患者肿瘤实质区FA值均较健侧正常脑组织降低(P均<0.05);星形细胞瘤患者肿瘤实质区ADC值较健侧正常脑组织高(P<0.05),脑膜瘤患者肿瘤实质区ADC值与健侧正常脑组织差异无统计学意义(P>0.05)。星形细胞瘤与脑膜瘤患者比较,肿瘤实质区ADC值、FA值差异有统计学意义(P均<0.05)。在DTT图中,星形细胞瘤多数表现为纤维束部分中断、受压、偏移或变形、移位;脑膜瘤纤维束呈现为稀疏、移位。结论 测量肿瘤实质区ADC值和FA值可鉴别脑内和脑外肿瘤如星形细胞瘤与脑膜瘤。DTT可清晰显示脑肿瘤对白质纤维束浸润、破坏和推移,有利于术前制定手术方案。     

Meningioma: a nursing perspective

A meningioma is an intracranial tumor arising from the coverings (meninges) of the brain. One of the first intracranial tumors successfully removed, the meningioma is considered the most common of all nongliomatous tumors, accounting for approximately 15 to 20% of all intracranial tumors. Occurring more than twice as often in women than men, meningiomas usually present between the third and sixth decades of life. It is imperative for nurses who work with neurosurgery patients to easily recognize and accurately assess specific characteristics of different brain tumors. Discussion in this article includes origin, signs and symptoms for various locations, diagnostic testing, medical treatment and nursing interventions for patients with meningiomas.     

动态磁敏感对比MR灌注成像对脑膜瘤分级的临床价值

目的 探讨不同类型脑膜瘤的动态磁敏感对比MR灌注成像(DSC-PWI)表现,评价DSC-PWI在脑膜瘤分级中的临床价值.方法 对92例经手术及病理证实的不同级别脑膜瘤患者在3.0 T MR扫描仪上术前进行常规MRI检查及DSC-PWI检查.分析其MRI灌注伪彩图像和灌注曲线,分别在肿瘤实质和瘤周水肿部分进行感兴趣区(R...     

18F-FDG PET颅内肿瘤显像特征和临床意义

目的探讨18F-脱氧葡萄糖(FDG)PET颅内肿瘤显像的影像特征和临床意义.方法对24例患者进行FDG PET颅脑显像,包括胶质瘤、脑膜瘤、脑转移瘤、部分颅内良性病变和正常者,并对结果进行半定量分析.结果 9例胶质瘤6例病灶FDG摄取高于正常灰质或与灰质相当,3例未见摄取异常;2例脑膜瘤患者病灶FDG摄取均低于正常白质;5例脑转移瘤3例病灶FDG摄取高于正常灰质,2例病灶摄取低于正常灰质;4例颅内良性病变2例病灶FDG摄取高于正常灰质,2例病灶摄取低于正常灰质.结论在FDG PET图像上,脑实质肿瘤(胶质瘤)和脑膜肿瘤存在差异,原发性颅内肿瘤和继发性肿瘤(脑转移瘤)也具有各自的影像特征.作为反映体内代谢状况的功能影像技术,FDG PET显像可提供颅内肿瘤类型、级别、预后和对治疗反映的重要信息.     

磁共振灌注成像诊断良恶性脑膜瘤

目的 探讨脑膜瘤相对性脑血流容积(rCBV)与脑膜瘤良恶性间的关系.方法 对36例经手术病理证实的脑膜瘤患者术前行常规MR及MR灌注成像(PWI)检查.PWI序列为GRE-EPI-T2~*WI,原始灌注图像数据经工作站软件计算出脑血流容积(CBV)图,获取脑膜瘤最大rCBV值,分析良恶性脑膜瘤肿瘤实质区与周围水肿区间rCBV值的差异.结果 良恶性脑膜瘤肿瘤实质区最大rCBV值分别为9.78±4.69、3.59±0.28 (t=7.168, P<0.001);周围水肿区最大rCBV值分别为3.06±1.76、3.58±1.93 (P>0.05).结论 MR PWI的rCBV值及CBV图是评价脑膜瘤良恶性的有价值的指标,对指导临床选择正确的治疗方案及评估预后具有重要意义.